CareCloud Inc (CCLD)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
$2.23-0.45%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
Intact: The reason to own it still holds.
CareCloud aims to double EPS to about $0.21 in 2026 from $0.10 in 2025. Revenue guidance is steady near $130 million. Adjusted EBITDA is targeted at $29 to $31 million. The company recently acquired Empower Healthcare to support growth.
The company is loss-making and volatile with a recent 34% stock drop. Revenue growth progress is mixed and EPS estimates for 2027 decline. Debt amendments and equity plans add uncertainty.
The price is about 54% below our fair value near $4.65. Analysts expect roughly 9% revenue growth. The market prices in a cautious outlook given recent losses and volatility.
Breaks if: Adjusted EBITDA falls below $27M in FY26
Breaks if: EPS falls below $0.10 in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
CCLD represents a cyclical investment in the healthcare sector, characterized by strong recent financial performance but volatile management. The current thesis state is intact, with management focused on significant earnings growth and revenue targets.
The market currently prices CCLD as justified, with a low fragility tier. Valuation is seen as cheap compared to peers, but there is an expectations gap indicating that some growth is already anticipated.
Management is on track to meet its earnings and revenue growth targets, although adjusted EBITDA results are mixed. Near-term risks include a low probability of missing guidance, but the company operates in a smaller-cap space where misses can be more common.
The thesis hinges on management's ability to maintain guidance and deliver on growth targets. Additionally, the performance of sector bellwethers and overall economic conditions, such as job growth, will significantly influence CCLD's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings report showed a miss. This miss raises concerns about future performance. The company has not provided new positive guidance. Overall, these factors suggest a less favorable outlook.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Achieve GAAP net income per share of $0.20 to $0.23 in 2026, representing a 100-130% increase from $0.10 in 2025.
Stated as a priority in 3 of last 3 quarters. Management reaffirmed 2026 EPS guidance of $0.20 to $0.23, a 100-130% increase from $0.10 in 2025. GAAP EPS was ($0.01) in 2026-Q1 and $0.00 in 2026-Q2, showing early progress but still below guidance midpoint. The trajectory shows delivering progress toward the EPS growth target.
“The Company is reaffirming its guidance for calendar year 2026 EPS $0.20 – $0.23.”
“EPS guidance of $0.20–$0.23 represents a 100-130% increase from the $0.10 achieved in full year 2025.”
“Reaffirming 2026 EPS guidance of $0.20 to $0.23 per share.”
Breaks if: Acquisition fails to contribute or causes material losses in FY26
Breaks if: Revenue falls below $120M in FY26
Overall, CCLD's fundamentals suggest a stable outlook, but external factors could impact its performance. Not investment advice.